ArticlePloS one2025
Dietary fiber inulin mitigates peripheral neuropathy in different stages of diabetes via modulating gut microbiota and metabolites in db/db mice.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathogenesis underlying diabetic peripheral neuropathy (DPN) remains largely elusive. Due to current unsatisfactory therapeutic approaches, new strategies for the control of DPN are needed. The present study was designed to assess whether inulin could serve as a potential neuroprotection against DPN in diverse stages of diabetes. Leptin receptor-mutant db/db mice were used as a model for DPN to dynamically assess the effects of inulin on DPN in diverse diabetic groups. According to blood glucose, the mice were randomly divided into prediabetes group (PDM group), inulin treated prediabetes group (INU/PDM group), diabetes group (DM group) and inulin treated diabetes group (INU/DM group). After 6 weeks of treatment, we found that inulin supplementation attenuated the neuropathic phenotypes in PDM and DM, including mechanical allodynia, thermal hyperalgesia and nerve conduction. Furthermore, inulin administration remarkably suppressed the levels of pro-inflammatory IL-6, TNF-α, and IL-17A in diverse diabetic groups with DPN, but increased an anti-inflammatory IL-10 in INU/PDM group, suggesting that dietary inulin intervention may suppress the DPN inflammation in different diabetic stages. Moreover, inulin supplementation markedly reduced the circulating LPS translocation. Metabolomics analysis revealed that inulin treatment significantly modulated the levels of 8 stage-specific metabolites; notably, it increased anti-inflammatory, anti-diabetic and neuroprotective metabolites taurine and dodecanoic acid in prediabetic mice, while decreasing pro-inflammatory mediators including oleamide and adrenic acid. In diabetic mice, inulin elevated metabolites including methylation (S-Adenosylmethionine), glucose homeostasis (glucose 6-phosphate), N-acetyl-L-phenylalanine and quinate. These metabolites are implicated in pathways such as bile acid metabolism, fatty acid oxidation, and neurotransmitter regulation, suggesting that inulin may exert neuroprotective effects by restoring metabolic homeostasis in a stage-dependent manner. Furthermore, rectification of gut dysbiosis by dietary inulin administration, with a major impact on increasing intestinal beneficial bacteria |(Bacteroides and Cyanobacteria) and decreasing pro-inflammatory bacteria (Ruminiclostridium_6, Mucispirillum, Deferribacteres and Tenericutes), exerted a close and complex interactions with metabolites, inflammatory factors, and peripheral neuropathic indicators. Collectively, dietary inulin intervention ameliorated DPN via reshaping gut microbial metabolism and suppressing inflammation, which may potentially provide an effective and safe therapeutics for the control of the disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.